Aclaris Therapeutics Inc. (NASDAQ:ACRS) rose 1.8% during trading on Thursday . The company traded as high as $21.22 and last traded at $20.52, with a volume of 55,831 shares changing hands. The stock had previously closed at $20.16.

ACRS has been the topic of a number of recent research reports. Zacks Investment Research upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 23rd. Jefferies Group upped their target price on Aclaris Therapeutics from $20.00 to $23.00 and gave the company a “buy” rating in a research report on Friday, August 12th. Finally, Guggenheim initiated coverage on Aclaris Therapeutics in a research report on Friday, June 10th. They issued a “buy” rating and a $35.00 target price on the stock. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $29.25.

The company’s market cap is $442.86 million. The company has a 50 day moving average of $20.07 and a 200-day moving average of $19.18.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Thursday, August 11th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by $0.01. Equities research analysts forecast that Aclaris Therapeutics Inc. will post ($2.61) earnings per share for the current year.

In other news, insider Kamil Ali-Jackson sold 3,738 shares of the firm’s stock in a transaction dated Friday, August 26th. The stock was sold at an average price of $20.35, for a total transaction of $76,068.30. Following the sale, the insider now owns 20,289 shares of the company’s stock, valued at approximately $412,881.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate, A-101 is being developed as an in-office treatment for seborrheic keratosis, a non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.